Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01084291 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01084291 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 18 participants.
The verdict
NCT01084291, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. There are four types of dengue virus, and infection with one does not offer protection against the others. This study will test whether a vaccine developed to prevent infection with dengue virus type 1 (DEN1) causes a response in people's immune system and is safe.
Interventions
- OTHER Placebo injection
- BIOLOGICAL Investigational Vaccine for DEN1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01084291
The ClinicalTrials.gov registry entry for NCT01084291 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo injection is the first listed.
NCT01084291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01084291 about?
NCT01084291 is a clinical study titled "Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine". Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. There are four types of dengue virus, and infection with one does not offer protection against the others. This study will test whether a vaccine developed t...
What is the current status of trial NCT01084291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-04. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01084291?
The interventions under investigation include: Placebo injection (OTHER), Investigational Vaccine for DEN1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01084291?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.